Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 2/20 | 0.72 |
| ▸ | CTSL | P07711 | 5/20 | 0.67 |
| ▸ | MME | P08473 | 2/20 | 0.66 |
| ▸ | BACE1 | P56817 | 1/20 | 0.61 |
| ▸ | CTSS | P25774 | 2/20 | 0.61 |
| ▸ | CTSK | P43235 | 2/20 | 0.61 |
| ▸ | CTSB | P07858 | 1/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9830466 | 1.00 | PSMB5 (0.72) | PSMB5CTSLMMEBACE1CTSS | |
| SCHEMBL10656896 | 0.95 | CTSL (0.70) | PSMB5CTSLMMEBACE1CTSS | |
| SCHEMBL2735614 | 0.95 | CTSL (0.70) | PSMB5CTSLMMEBACE1CTSS | |
| SCHEMBL4356229 | 0.89 | ACE (0.68) | PSMB5CTSLMMECTSSCTSK | |
| SCHEMBL4357736 | 0.89 | ACE (0.68) | PSMB5CTSLMMECTSSCTSK | |
| SCHEMBL6032313 | 0.89 | PSMB5 (0.67) | PSMB5CTSLBACE1CTSSCTSK | |
| SCHEMBL9829021 | 0.88 | OPRM1 (0.62) | PSMB5CTSLMMECTSBFOLH1 | |
| SCHEMBL9829089 | 0.88 | OPRM1 (0.62) | PSMB5CTSLMMECTSBFOLH1 | |
| SCHEMBL7292059 | 0.88 | MME (0.71) | MMEFOLH1 | |
| SCHEMBL9832280 | 0.88 | ACE (0.64) | PSMB5CTSLMMEFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190315693-A1 | APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | RES TRIANGLE INST (US) | 2019-10-17 | — | — | US | disclosed |
| US-10377718-B2 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2019-08-13 | — | — | US | disclosed |
| US-20160207889-A1 | APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | RESEARCH TRIANGLE INSTITUTE | 2016-07-21 | — | — | US | disclosed |
| WO-2015188073-A1 | APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | RESEARCH TRIANGLE INSTITUTE (US) | 2015-12-10 | — | — | WO | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207889-A1 | APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | APLNR, AP1G1, APMAP | PSMB5 3507/4885CTSL 898/4885MME 701/4885 |
| US-10377718-B2 | Apelin receptor (APJ) agonists and uses thereof | APLNR, AP1G1, APMAP | PSMB5 3507/4885CTSL 898/4885MME 701/4885 |
| US-20190315693-A1 | APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | APLNR, AP1G1, APMAP | PSMB5 3507/4885CTSL 898/4885MME 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.